We use cookies to enhance the usability of our website. If you continue, we'll assume that you are happy to receive all cookies. More information. Don't show this again.
RPL8
SECTIONS
  • TISSUE
  • BRAIN
  • SINGLE CELL TYPE
  • TISSUE CELL TYPE
  • PATHOLOGY
  • DISEASE
  • IMMUNE CELL
  • BLOOD PROTEIN
  • SUBCELLULAR
  • CELL LINE
  • STRUCTURE
  • INTERACTION
ABOUT
  • INTRODUCTION
  • HISTORY
  • ORGANIZATION
  • PUBLICATIONS
  • ANTIBODY SUBMISSION
  • ANTIBODY AVAILABILITY
  • ACKNOWLEDGMENTS
  • CONTACT
NEWS
  • NEWS ARTICLES
  • PRESS ROOM
LEARN
  • DICTIONARY
  • PROTEIN CLASSES
  • PROTEIN EVIDENCE
  • METHODS
  • EDUCATIONAL VIDEOS
DATA
  • DOWNLOADABLE DATA
  • PUBLICATION DATA
  • RELEASE HISTORY
  • SARS-COV-2
HELP
  • ANTIBODY VALIDATION
  • ASSAYS & ANNOTATION
  • DISCLAIMER
  • HELP & FAQ
  • PRIVACY STATEMENT
  • LICENCE & CITATION
Fields »
Search result

Field
Term
Gene name
Class
Subclass
Class
Keyword
Chromosome
External id
Tissue
Cell type
Expression
Patient ID
Tissue
Category
Cluster
Reliability
Brain region
Category
Brain region
Category
Brain region
Category
Cluster
Reliability
Cell type
Category
Cluster
Tissue
Cell type
Enrichment
Cancer
Prognosis
Cancer
Category
Cell type
Category
Cell lineage
Category
Cluster
Annotation
Disease
Location
Searches
Location
Cell line
Type
Phase
Reliability
Cancer type
Category
Cluster
Interacting gene
Number of interactions
Pathway
Category
Score
Score
Score
Validation
Validation
Validation
Validation
Antibodies
Protein structure
In atlas
Column


  • SUMMARY

  • TISSUE

  • BRAIN

  • SINGLE CELL

  • TISSUE CELL

  • PATHOLOGY

  • DISEASE

  • IMMUNE

  • BLOOD

  • SUBCELL

  • CELL LINE

  • STRUCTURE

  • INTERACTION

  • RPL8
PATHOLOGY TESTIS CANCER Show tissue menu
BREAST CANCER CARCINOID CERVICAL CANCER COLORECTAL CANCER ENDOMETRIAL CANCER GLIOMA HEAD AND NECK CANCER LIVER CANCER LUNG CANCER LYMPHOMA
MELANOMA OVARIAN CANCER PANCREATIC CANCER PROSTATE CANCER RENAL CANCER SKIN CANCER STOMACH CANCER TESTIS CANCER THYROID CANCER UROTHELIAL CANCER
ANTIBODIES
AND
VALIDATION
Dictionary
Testis cancer
Human pathology
Testis cancer
TESTIS CANCER - Interactive survival scatter ploti

The Survival Scatter plot shows the clinical status (i.e. dead or alive) for all individuals in the patient cohort, based on the same data that underlies the corresponding Kaplan-Meier plots. Patients that are alive at last time for follow-up are shown in blue and patients who have died during the study are shown in red.

The x-axis shows the expression levels (FPKM) of the investigated gene in the tumor tissue at the time of diagnosis. The y-axis shows the follow-up time after diagnosis (years). Both axes are complimented with kernel density curves demonstrating the data density over the axes. The top density plot shows the expression levels (FPKM) distribution among dead (red) and alive patients (blue). The right density plot shows the data density of the survived years of dead patients with high and low expression levels respectively, stratified using the cutoff indicated by the vertical dashed line through the Survival Scatter plot. This cutoff is automatically defined based on the FPKM cutoff that minimizes the p-score. The cutoff can be changed by dragging the vertical line or by entering a cutoff value in the square labeled "Current cut-off".

Under the Survival Scatter plot the p-score landscape (black curve; left axis) is shown together with dead median separation (red curve; right axis). Dead median separation is the difference in median mRNA expression between patients who have died with high and low expression, respectively. It is calculated as follows: median FPKM expression of dead patients with high expression - median FPKM expression of dead patients with low expression. This is intended to aid the user in visually exploring custom cutoffs and the associated p-scores and dead median separation.

Individual patient data is displayed and can be filtered by clicking on one or more of the category buttons on the top of the page. Categories describing expression level and patient information include: high, low, alive, dead, female, male and tumor stages. The scale of the x-axis can be toggled between linear and log-scale by clicking on the "x log" button. Mouse-over function shows TCGA ID, patient information and mRNA expression (FPKM) for each patient.

& Survival analysisi

Kaplan-Meier plots summarize results from analysis of correlation between mRNA expression level and patient survival. Patients were divided based on level of expression into one of the two groups "low" (under cut off) or "high" (over cut off). X-axis shows time for survival (years) and y-axis shows the probability of survival, where 1.0 corresponds to 100 percent.

RPL8 is not prognostic in testis cancer


Stage:


Survival analysis
Current cut offi

Current cut-off shows the cut-off (FPKM) currently selected. It may be changed manually. When the current cut-off is changed, the vertical dashed line indicating cut-off, the interactive survival scatter plot and the Kaplan-Meier curve will be automatically adjusted to show results accordingly.

:
Best expression cut offi

Based on the FPKM value of each gene, patients were classified into two groups and association between prognosis (survival) and gene expression (FPKM) was examined. The best expression cut-off refers the FPKM value that yields maximal difference with regard to survival between the two groups at the lowest log-rank P-value. Best expression cut-off was selected based on survival analysis .

When clicking on this number, the vertical dashed line indicating cut-off, the interactive survival plot, and the Kaplan-Meier curve will be adjusted to show results based on the best expression cut-off.

: 1923.34
Median expressioni

Median expression refers to the median FPKM value calculated based on the gene expression (FPKM) data from all patients in this dataset. When clicking on this number, the vertical dashed line indicating cut-off, the interactive survival plot, and the Kaplan-Meier curve will be adjusted to show results based on the median expression.

: N/A
Median follow up timei

Median follow up time refers to the median time (years) after diagnosis with this type of cancer, based on clinical data from all patients in this dataset.

: N/A
P scorei

Log-rank P value for Kaplan-Meier plot showing results from analysis of correlation between mRNA expression level and patient survival.

N/A
5-year survival highi

5-year survival for patients with higher expression than the expression cutoff.

For melanoma and glioma, 3-year survival is shown.

N/A
5-year survival lowi

5-year survival for patients with lower expression than the expression cutoff.

For melanoma and glioma, 3-year survival is shown.

N/A
TCGA RNA samplesi

RNA-seq data is reported as average FPKM (number Fragments Per Kilobase of exon per Million reads), generated by the The Cancer Genome Atlas (TCGA) .

Normal distribution across the dataset is visualized with box plots, shown as median and 25th and 75th percentiles. Points are displayed as outliers if they are above or below 1.5 times the interquartile range. FPKM values of the individual samples are presented next to the box plot.

Average FPKM 1526.1
Number of samples 134
Samples
Sample Description FPKM
TCGA-2G-AAFN-01A 26 years, male, white, stage:iiib, alive, 773 days 4653.2
TCGA-2G-AAL7-01A 32 years, male, white, stage:is, alive, 3991 days 3791.5
TCGA-2G-AAFM-01A 31 years, male, white, stage:iia, alive, 503 days 3413.5
TCGA-2G-AAHP-01A 31 years, male, white, stage:is, alive, 5667 days 3118.7
TCGA-VF-A8A8-01A 18 years, male, white, stage:ia, alive, 1131 days 3073.5
TCGA-W4-A7U4-01A 23 years, male, white, alive, 738 days 3007.1
TCGA-2G-AAKL-01A 26 years, male, white, stage:ii, alive, 7023 days 2932.9
TCGA-2G-AAKG-01A 22 years, male, white, stage:i, alive, 6598 days 2895.3
TCGA-2G-AAHL-01A 26 years, male, white, stage:i, alive, 7081 days 2807.0
TCGA-XE-AANR-01A 24 years, male, white, stage:i, alive, 14 days 2800.9
TCGA-2G-AAGW-01A 38 years, male, white, stage:is, alive, 4899 days 2708.1
TCGA-WZ-A8D5-01A 38 years, male, white, alive, 774 days 2649.2
TCGA-SB-A6J6-01A 22 years, male, white, stage:ia, alive, 413 days 2611.7
TCGA-4K-AAAL-01A 31 years, male, white, stage:is, alive, 483 days 2606.6
TCGA-2G-AAEX-01A 38 years, male, white, stage:is, alive, 1259 days 2499.4
TCGA-SN-A84Y-01A 18 years, male, white, stage:is, alive, 524 days 2482.8
TCGA-2G-AAFI-01A 41 years, male, white, stage:ib, alive, 675 days 2464.9
TCGA-VF-A8AE-01A 39 years, male, white, stage:ia, alive, 727 days 2459.3
TCGA-2G-AAGA-01A 38 years, male, white, stage:iia, alive, 2439 days 2413.1
TCGA-2G-AAGZ-01A 27 years, male, white, stage:iiia, alive, 5233 days 2389.4
TCGA-SN-A84X-01A 21 years, male, white, stage:is, alive, 312 days 2285.8
TCGA-2G-AAGN-01A 41 years, male, white, stage:iiib, alive, 3656 days 2284.0
TCGA-4K-AA1I-01A 26 years, male, white, stage:ia, alive, 3 days 2223.0
TCGA-2G-AAG8-01A 21 years, male, white, stage:ib, alive, 2289 days 2150.8
TCGA-2G-AAGO-01A 41 years, male, white, stage:is, alive, 4026 days 2124.1
TCGA-WZ-A7V3-01A 20 years, male, white, stage:i, alive, 753 days 2058.3
TCGA-2G-AAFO-01A 33 years, male, white, stage:iia, alive, 685 days 2039.0
TCGA-2G-AAFL-01A 35 years, male, white, stage:ib, alive, 750 days 2024.0
TCGA-XE-A8H1-01A 24 years, male, white, stage:is, alive, 209 days 2020.0
TCGA-2G-AAGC-01A 28 years, male, white, stage:is, alive, 2585 days 1981.5
TCGA-S6-A8JX-01A 27 years, male, white, stage:ib, alive, 552 days 1980.8
TCGA-YU-A90W-01A 45 years, male, white, stage:ia, alive, 1113 days 1978.3
TCGA-2G-AAGF-01A 28 years, male, white, stage:is, alive, 2734 days 1924.7
TCGA-YU-A90Y-01A 23 years, male, black or african american, stage:iiic, dead, 17 days 1922.0
TCGA-VF-A8AD-01A 36 years, male, white, stage:ib, alive, 1006 days 1876.7
TCGA-XE-AANJ-01A 39 years, male, white, stage:is, alive, 2007 days 1869.4
TCGA-ZM-AA06-01A 45 years, male, white, stage:ib, alive, 1498 days 1845.5
TCGA-2G-AAFY-01A 24 years, male, white, stage:iia, alive, 1099 days 1844.9
TCGA-SN-A6IS-01A 26 years, male, white, stage:is, alive, 496 days 1804.5
TCGA-2G-AAH8-01A 45 years, male, white, stage:iiic, alive, 2248 days 1792.8
TCGA-2G-AAGE-01A 21 years, male, white, stage:is, alive, 2478 days 1774.1
TCGA-2G-AAKD-01A 18 years, male, white, stage:iii, alive, 6340 days 1770.6
TCGA-XY-A9T9-01A 37 years, male, white, stage:is, alive, 281 days 1762.4
TCGA-SB-A76C-01A 38 years, male, white, alive, 42 days 1730.8
TCGA-XY-A8S2-01A 67 years, male, white, stage:i, alive, 672 days 1719.2
TCGA-2G-AAHG-01A 25 years, male, white, stage:i, alive, 1819 days 1702.5
TCGA-WZ-A7V5-01A 27 years, male, white, stage:i, alive, 1061 days 1667.4
TCGA-2G-AALP-01A 43 years, male, white, stage:iiib, alive, 2645 days 1662.1
TCGA-2G-AAG3-01A 53 years, male, white, stage:is, alive, 1593 days 1632.0
TCGA-2G-AAFG-01A 30 years, male, white, stage:is, alive, 6183 days 1628.9
TCGA-XE-A8H5-01A 29 years, male, stage:is, alive, 1217 days 1608.0
TCGA-2G-AAF4-01A 30 years, male, white, stage:i, alive, 2315 days 1601.6
TCGA-XE-AAO3-01A 33 years, male, asian, stage:i, alive, 2857 days 1580.7
TCGA-XE-AAOD-01A 39 years, male, white, stage:ib, alive, 2058 days 1574.9
TCGA-XE-AAOF-01A 50 years, male, asian, stage:ia, alive, 1268 days 1574.2
TCGA-2G-AAGJ-01A 28 years, male, black or african american, stage:ia, alive, 2938 days 1552.0
TCGA-ZM-AA0B-01A 32 years, male, white, stage:ia, alive, 838 days 1542.3
TCGA-XY-A8S3-01B 24 years, male, white, stage:is, alive, 843 days 1497.4
TCGA-ZM-AA0N-01A 44 years, male, white, stage:ib, alive, 634 days 1476.6
TCGA-2G-AAKM-01A 14 years, male, white, stage:ii, dead, 6972 days 1454.8
TCGA-ZM-AA0E-01A 39 years, male, white, stage:ia, alive, 811 days 1445.7
TCGA-XE-A9SE-01A 35 years, male, white, stage:ia, alive, 708 days 1431.4
TCGA-2G-AAHC-01A 33 years, male, white, stage:is, alive, 5539 days 1425.8
TCGA-S6-A8JY-01A 27 years, male, white, stage:is, alive, 278 days 1411.0
TCGA-2G-AAH3-01A 20 years, male, white, stage:i, alive, 1822 days 1410.7
TCGA-VF-A8AC-01A 29 years, male, white, stage:ia, alive, 1083 days 1396.3
TCGA-VF-A8A9-01A 31 years, male, white, stage:ia, alive, 1119 days 1390.5
TCGA-2X-A9D5-01A 49 years, male, white, stage:i, alive, 435 days 1365.7
TCGA-YU-A912-01A 34 years, male, black or african american, stage:iiic, alive, 866 days 1357.1
TCGA-XE-A8H4-01A 23 years, male, white, stage:ia, alive, 559 days 1356.6
TCGA-XE-AAO4-01A 40 years, male, white, stage:ia, alive, 367 days 1352.9
TCGA-YU-A90P-01A 25 years, male, white, stage:ia, alive, 2069 days 1347.5
TCGA-2G-AAKH-01A 19 years, male, white, stage:ii, alive, 6862 days 1343.3
TCGA-W4-A7U2-01A 26 years, male, white, alive, 1263 days 1338.5
TCGA-2G-AAH0-01A 30 years, male, white, stage:is, alive, 5477 days 1322.0
TCGA-YU-AA61-01A 29 years, male, white, stage:is, alive, 864 days 1311.4
TCGA-2G-AAGK-01A 20 years, male, white, stage:is, alive, 3621 days 1307.7
TCGA-2G-AAGS-01A 39 years, male, white, stage:iiib, alive, 4816 days 1304.8
TCGA-2G-AAG0-01A 23 years, male, white, stage:is, alive, 1529 days 1300.1
TCGA-2G-AAFE-01A 37 years, male, white, stage:iia, alive, 4702 days 1290.1
TCGA-YU-A94D-01A 28 years, male, stage:iiib, alive, 2167 days 1279.3
TCGA-SO-A8JP-01A 29 years, male, white, stage:i, alive, 540 days 1234.7
TCGA-VF-A8AA-01A 51 years, male, white, stage:i, alive, 1146 days 1215.9
TCGA-2G-AAHN-01A 32 years, male, white, stage:i, alive, 6445 days 1213.5
TCGA-2G-AAF8-01A 33 years, male, white, stage:ia, alive, 3911 days 1212.7
TCGA-XE-AAO6-01A 47 years, male, white, stage:ia, alive, 240 days 1206.8
TCGA-X3-A8G4-01A 33 years, male, white, stage:is, alive, 856 days 1206.6
TCGA-2G-AAF6-01A 28 years, male, white, stage:is, alive, 3491 days 1205.7
TCGA-XE-AANV-01A 52 years, male, stage:ib, alive, 1701 days 1190.7
TCGA-2G-AAFH-01A 38 years, male, white, stage:iib, alive, 1375 days 1178.9
TCGA-2G-AAG9-01A 25 years, male, white, stage:iiib, alive, 2234 days 1156.7
TCGA-S6-A8JW-01A 37 years, male, white, stage:is, alive, 698 days 1136.3
TCGA-2G-AAH4-01A 34 years, male, white, stage:ii, alive, 6210 days 1094.5
TCGA-2G-AAH2-01A 20 years, male, white, stage:is, alive, 6060 days 1075.2
TCGA-YU-A90Q-01A 21 years, male, stage:ib, alive, 1964 days 1053.2
TCGA-2G-AAHT-01A 32 years, male, white, stage:is, alive, 542 days 1027.9
TCGA-XE-AAOJ-01A 24 years, male, white, stage:is, alive, 1550 days 1026.7
TCGA-2G-AAEW-01A 31 years, male, white, stage:is, dead, 618 days 1013.5
TCGA-ZM-AA0H-01A 50 years, male, white, stage:is, alive, 1736 days 1012.4
TCGA-VF-A8AB-01A 31 years, male, black or african american, stage:ia, alive, 760 days 1002.3
TCGA-XE-AAOL-01A 38 years, male, black or african american, stage:i, alive, 13 days 1001.3
TCGA-XY-A89B-01A 35 years, male, white, stage:ia, alive, 471 days 998.6
TCGA-2G-AAFZ-01A 32 years, male, white, stage:iii, alive, 1353 days 985.6
TCGA-XE-AAOB-01A 27 years, male, white, stage:is, dead, 513 days 984.6
TCGA-WZ-A7V4-01A 28 years, male, white, stage:i, alive, 894 days 971.1
TCGA-ZM-AA0D-01A 34 years, male, white, stage:ia, alive, 848 days 945.3
TCGA-2G-AAG7-01A 33 years, male, white, stage:is, alive, 2475 days 912.3
TCGA-2G-AAGV-01A 23 years, male, white, alive, 4527 days 890.2
TCGA-ZM-AA0F-01A 35 years, male, white, stage:ia, alive, 681 days 857.5
TCGA-4K-AA1H-01A 26 years, male, white, stage:ia, alive, 518 days 853.7
TCGA-2G-AAF1-01A 28 years, male, asian, stage:is, alive, 1403 days 852.5
TCGA-2G-AAL5-01A 31 years, male, white, stage:i, alive, 7437 days 815.4
TCGA-ZM-AA05-01A 36 years, male, white, stage:iic, alive, 1126 days 807.7
TCGA-2G-AAGM-01A 51 years, male, white, stage:is, alive, 3891 days 807.5
TCGA-2G-AAGX-01A 22 years, male, white, stage:ia, alive, 5514 days 765.7
TCGA-YU-A90S-01A 26 years, male, white, stage:ia, alive, 971 days 747.9
TCGA-2G-AAHA-01A 48 years, male, white, stage:ib, alive, 3349 days 743.8
TCGA-2G-AAGT-01A 30 years, male, white, stage:is, alive, 4406 days 703.2
TCGA-YU-AA4L-01A 27 years, male, black or african american, stage:iiic, alive, 1573 days 701.3
TCGA-2G-AAGI-01A 33 years, male, white, stage:is, alive, 3137 days 666.2
TCGA-4K-AA1G-01A 34 years, male, white, stage:is, alive, 436 days 663.6
TCGA-2G-AAG6-01A 24 years, male, white, stage:is, alive, 2231 days 655.2
TCGA-2G-AAGP-01A 33 years, male, white, stage:iia, alive, 4018 days 643.2
TCGA-2G-AAFV-01A 31 years, male, white, stage:is, alive, 1389 days 582.5
TCGA-2G-AAGG-01A 20 years, male, white, stage:iiic, alive, 2611 days 558.3
TCGA-2X-A9D6-01A 42 years, male, white, stage:i, alive, 607 days 544.9
TCGA-2G-AAG5-01A 36 years, male, white, stage:is, alive, 2299 days 524.2
TCGA-W4-A7U3-01A 26 years, male, white, alive, 149 days 500.8
TCGA-SN-A84W-01A 30 years, male, white, stage:is, alive, 293 days 492.3
TCGA-YU-A94I-01A 66 years, male, stage:ia, alive, 536 days 447.5
TCGA-XE-AAOC-01A 31 years, male, white, stage:ia, alive, 270 days 445.5
TCGA-2G-AAFJ-01A 23 years, male, asian, alive, 792 days 442.7
TCGA-2G-AAGY-01A 28 years, male, white, stage:is, alive, 5329 days 374.9
TCGA-XE-AANI-01A 37 years, male, white, stage:is, alive, 1041 days 339.1
Show allShow less
TESTIS CANCER - Protein expressioni

A mouse-over function shows sample information and annotation data. Click on an image to view it in a full screen mode. Samples can be filtered based on level of antibody staining by selecting one or several of the following categories: high, medium, low and not detected. The assay and annotation is described here.

Note that samples used for immunohistochemistry by the Human Protein Atlas do not correspond to samples in the TCGA dataset.

 

Antibody stainingi

Antibody staining in the annotated cell types in the current human tissue is reported as not detected, low, medium, or high, based on conventional immunohistochemistry profiling in selected tissues. This score is based on the combination of the staining intensity and fraction of stained cells.

Each image is clickable and will lead to virtual microscopy that enables deeper exploration of all samples and also displays staining intensity scores, fraction scores and subcellular localization as well as patient and tissue information for each sample.


Antibody HPA045095

Antibody HPA050165
 Staining
  High
  Medium
  Low
  Not detected
 Intensity
  Strong
  Moderate
  Weak
  Negative
 Quantity
  >75%
  75%-25%
  <25%
  None
 Location
  Nuclear
  Cytoplasmic/membranous
  Cytoplasmic/membranous,nuclear
  None
Click images for details

Contact

  • NEWS ARTICLES
  • PRESS ROOM

The Project

  • INTRODUCTION
  • ORGANIZATION
  • PUBLICATIONS

The Human Protein Atlas

  • DOWNLOADABLE DATA
  • LICENCE & CITATION
  • HELP & FAQ
The Human Protein Atlas project is funded
by the Knut & Alice Wallenberg Foundation.


contact@proteinatlas.org